{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:09:41Z","timestamp":1790766581787,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,8,30]],"date-time":"2011-08-30T00:00:00Z","timestamp":1314662400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1038\/bjc.2011.334","type":"journal-article","created":{"date-parts":[[2011,8,30]],"date-time":"2011-08-30T20:06:26Z","timestamp":1314734786000},"page":"884-889","source":"Crossref","is-referenced-by-count":50,"title":["Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer"],"prefix":"10.1038","volume":"105","author":[{"given":"F A","family":"Raja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C L","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Hirte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M K","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Swart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,30]]},"reference":[{"key":"BFbjc2011334_CR1","unstructured":"Aghajanian C, Finkler NJ, Rutherford T, Smith DA, Yi J, Parmar H, Nycum LR, Sovak MA (2011) OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 29 (Suppl 18): abstr LBA5007"},{"issue":"Suppl 8","key":"BFbjc2011334_CR2","first-page":"viii4","volume":"21","author":"T Batchelor","year":"2010","unstructured":"Batchelor T, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Xu J, Liu Q, van den Bent M (2010) A Phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients. Ann Oncol 21 (Suppl 8): viii4 LBA7","journal-title":"Ann Oncol"},{"key":"BFbjc2011334_CR3","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1200\/jco.2007.25.18_suppl.554","volume":"25","author":"N Denduluri","year":"2007","unstructured":"Denduluri N, Berman AW, Vatas U, Chow CK, Rosing DR, Swain SM (2007) Cardiotoxicity after doxorubicin and AZD2171, an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, in patients (pts) with breast cancer. J Clin Oncol 25(Suppl 18s): 554","journal-title":"J Clin Oncol"},{"issue":"1","key":"BFbjc2011334_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1200\/JCO.2009.22.9427","volume":"28","author":"GD Goss","year":"2010","unstructured":"Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28 (1): 49\u201355","journal-title":"J Clin Oncol"},{"issue":"20 suppl","key":"BFbjc2011334_CR5","doi-asserted-by":"publisher","first-page":"abstr 5521","DOI":"10.1200\/jco.2008.26.15_suppl.5521","volume":"26","author":"HW Hirte","year":"2008","unstructured":"Hirte HW, Vidal L, Fleming GF, Sugimoto AK, Morgan RJ, Biagi JJ, Wang L, McGill S, Ivy SP, Oza AM (2008) A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. J Clin Oncol 26 (20 suppl): abstr 5521","journal-title":"J Clin Oncol"},{"issue":"33","key":"BFbjc2011334_CR6","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","volume":"27","author":"UA Matulonis","year":"2009","unstructured":"Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT (2009) Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27 (33): 5601\u20135606","journal-title":"J Clin Oncol"},{"issue":"9375","key":"BFbjc2011334_CR7","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"MK Parmar","year":"2003","unstructured":"Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C (2003) Paclitaxel plus platinum-based chemotherapy vs conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet 361 (9375): 2099\u20132106","journal-title":"Lancet"},{"issue":"29","key":"BFbjc2011334_CR8","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stahle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Luck HJ, Rochon J, Zimmermann AH, Eisenhauer E (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 (29): 4699\u20134707","journal-title":"J Clin Oncol"},{"issue":"20","key":"BFbjc2011334_CR9","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28 (20): 3323\u20133329","journal-title":"J Clin Oncol"},{"issue":"Suppl 8","key":"BFbjc2011334_CR10","first-page":"viii188","volume":"21","author":"HJ Schmoll","year":"2010","unstructured":"Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Barker P, Mookerjee B, Robertson J, Cutsem EV, Group obotHIs (2010) mFOLFOX6 + cediranib vs mFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer (mCRC): a randomized, double-blind, Phase II\/III study (HORIZON III). Ann Oncol 21 (Suppl 8): viii188, abs 580O","journal-title":"Ann Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2011334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011334","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:03:09Z","timestamp":1684414989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2011334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,30]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["BFbjc2011334"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2011.334","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,30]]}}}